Abstract: COVID-19 is a contagious disease, so there is a potential for an increase in
the number of COVID-19 cases. If there is an increase in incidence or prevalence, it will
cause problems related to the costs and outcomes of an intervention. Therefore, a costeffectiveness analysis is needed. This study aims to determine the cost-effectiveness of
COVID-19 patients who use oxygen therapy with and without being given remdesivir.
This study uses a cost-effectiveness analysis method that takes into account the ACER
(Average Cost-Effectiveness Ratio) and ICER (Incremental Cost-Effectiveness Ratio)
values. The data used is retrospective data and sampling is done by purposive
sampling, the sample obtained in this study amounted to 34 cases. The results of this
study showed that the total average direct medical costs of the remdesivir group were
Rp. 32,399,532 with an effectiveness of 47%, while in the non-remdesivir group the
total average direct medical costs were Rp 26,853,729 with an effectiveness of 41%.
The ACER value obtained in this study was Rp. 688,490 in the remdesivir group and
Rp. 654,969 in the non-remdesivir group. The results of the ICER calculation in this
study were Rp. 924,301 per day of hospitalization. In this study, it can be concluded
that the therapy group of COVID-19 patients who use oxygen therapy without being
given remdesivir is more cost-effective than the therapy group of COVID-19 patients
who use oxygen therapy with remdesivir.
Keywords: remdesivir; oxygen therapy, length of hospital stay, COVID-19, costeffectiveness analysis